Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 4 days ago
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.
30 May 2017
Pain is a multidimensional experience that often requires a combination of various approaches to bring about optimal outcomes. At a recent scientific symposium held during the 7th Association of South-East Asian Pain Societies Congress held in Yangon, Myanmar, Professor Stefano Coaccioli discussed the evolution of ns-NSAIDs and how dexketoprofen trometamol (Ketesse®; A. Menarini) can improve acute pain management.

Switching between biologic classes improves drug survival in psoriasis patients

17 Dec 2019

Biologic therapies for psoriasis may need to be switched between classes to increase drug survival in patients, suggest a recent study. Ad hoc retrospective studies are needed to confirm the benefits of this switching strategy.

“Biologic therapy for psoriasis is effective but not always long-lasting and sometimes needs to be switched,” the investigators said.

Of the 195 psoriasis patients included in this study, 90.6 percent achieved a reduction of ≥75 percent in their baseline Psoriasis Area and Severity Index (PASI) score. Ustekinumab (47/169; 27.8 percent) was the most commonly used biologic in 2018. Furthermore, those with higher baseline PASI scores had a higher likelihood of switching biologic therapies (odds ratio, 1.08; p=0.0399).

Drug survival with ustekinumab was longer (>7.0 years) in naïve patients, but no significant differences were seen in biologic-experienced patients. Prior treatment with biologic therapies increased the need for switching (hazard ratio [HR], 1.20; p=0.14). In addition, drug survival was longer when switching between biologic classes than when switching within biologic classes (HR, 0.48; p=0.003).

This study retrospectively observed 195 patients with psoriasis who were treated during 2006–2018. The investigators performed descriptive statistical analyses and logistic regression models. They also used Kaplan–Meier survival curves and multivariable Cox models adjusted for confounding variable to estimate and compare drug survival.

The study was limited by its single-centre, retrospective real-life design, which produced data that were “not perfectly homogenous.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 4 days ago
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.
30 May 2017
Pain is a multidimensional experience that often requires a combination of various approaches to bring about optimal outcomes. At a recent scientific symposium held during the 7th Association of South-East Asian Pain Societies Congress held in Yangon, Myanmar, Professor Stefano Coaccioli discussed the evolution of ns-NSAIDs and how dexketoprofen trometamol (Ketesse®; A. Menarini) can improve acute pain management.